BIOMAT Database Logo BIOMAT Database Logo

BCR-ABL antisense purging in chronic myeloid leukaemia. 1993

M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias
D016178 Granulocyte-Macrophage Colony-Stimulating Factor An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. CSF-GM,Colony-Stimulating Factor, Granulocyte-Macrophage,GM-CSF,Histamine-Producing Cell-Stimulating Factor,CSF-2,TC-GM-CSF,Tumor-Cell Human GM Colony-Stimulating Factor,Cell-Stimulating Factor, Histamine-Producing,Colony Stimulating Factor, Granulocyte Macrophage,Granulocyte Macrophage Colony Stimulating Factor,Histamine Producing Cell Stimulating Factor,Tumor Cell Human GM Colony Stimulating Factor
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense

Related Publications

M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman
bcr-abl in chronic myeloid leukaemia.
August 1986, Lancet (London, England),
M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman
Residual bcr/abl transcripts in chronic myeloid leukaemia.
February 1990, Lancet (London, England),
M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman
Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
October 1993, Stem cells (Dayton, Ohio),
M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman
A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia.
October 2014, Cancer chemotherapy and pharmacology,
M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman
Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
December 1995, Leukemia & lymphoma,
M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman
Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR.
May 1995, British journal of haematology,
M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman
Dual transcripts of BCR-ABL & different polymorphisms in chronic myeloid leukaemia patients.
May 2016, The Indian journal of medical research,
M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman
BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.
January 2001, Leukemia & lymphoma,
M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman
Detection of BCR-ABL transcripts in chronic myeloid leukaemia by nested PCR.
February 1999, Leukemia research,
M A Kirkland, and S G O'Brien, and C McDonald, and R J Davidson, and N C Cross, and J M Goldman
An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism.
February 1997, British journal of haematology,
Copied contents to your clipboard!